1st patient treated in Kuros Biosciences spinal fusion trial

Alan Condon -   Print  |
Listen

Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease.

Fibrin-PTH is a drug-biologic that promotes bone growth through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and increasing the lifespan of bone-forming cells.

University of California San Diego's Richard Allen, MD, PhD, principal investigator of the study, treated the first patient.

The phase 2 study is evaluating the technology for both open and minimally invasive surgical techniques.

Fifty patients will be enrolled in the trial, with those treated with local autograft acting as controls.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers